Cargando…
Biosimilars for Rheumatoid Arthritis: Riding the 2023 Wave [Podcast]
This article discusses some of the queries and concerns that patients may have about initiating or switching to treatment with a biosimilar for rheumatoid arthritis following the US 2023 release of several biosimilars of the adalimumab reference product, also known by the brand name, Humira. The art...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10625413/ https://www.ncbi.nlm.nih.gov/pubmed/37927492 http://dx.doi.org/10.2147/OARRR.S443235 |